Stay updated with breaking news from Esm Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Southwest Gas is committed to our customers and the communities we serve and helping to reduce economy-wide emissions to support a more...
/PRNewswire/ -- Southwest Gas is committed to our customers and the communities we serve and helping to reduce economy-wide emissions to support a more...
BILLERICA, Mass., March 14, 2022 -- Conformis, Inc. announced today that Denise Pedulla has joined the Company as its Chief Legal Officer and Corporate Secretary. “We are pleased to... | March 14, 2022
New services address the exponential growth and interest in crypto and harness fintech & crypto experts across the globe to provide knowledgeable, always-on support. SUNNYVALE, CA / ACCESSWIRE / June
Published: May 01, 2021 Expanded indications for patients with sickle cell disease or other anemias, as well as thalassemia BOSTON, May 1, 2021 /PRNewswire/ -- Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), announced today that the U.S. Food & Drug Administration (FDA) has approved FERRIPROX ® (deferiprone) for the treatment of transfusional iron overload due to sickle cell disease (SCD) or other anemias in adult and pediatric patients 3 years of age and older.* This FDA approval expands the ...